Keyphrases
5-year Survival
12%
Activity-dependent
12%
Albinism
12%
Alemtuzumab
12%
Antithymocyte Globulin
12%
Conditioning Time
12%
Confidence Interval
25%
Etoposide
100%
Genetic Disease
12%
Haploidentical
12%
Hematopoietic Stem Cell Transplantation
87%
HLH-2004
25%
Hyperinflammatory Syndrome
12%
Life-threatening
12%
Lymphocyte Cytotoxicity
12%
Mepolizumab
12%
Newborn Screening
12%
Novel Treatments
12%
Patient Diagnosis
12%
Patient Survival
12%
Potential Gains
12%
Primary Hemophagocytic Lymphohistiocytosis
100%
Reduced Time
12%
Reduced Toxicity Conditioning
12%
Ruxolitinib
12%
Salvage Therapy
12%
Standard of Care
12%
Survival Probability
25%
Treatment Regime
12%
X-linked Lymphoproliferative Disease
12%
Medicine and Dentistry
Albinism
12%
Alemtuzumab
12%
Conditioning
12%
Emapalumab
12%
Etoposide
100%
Graft Survival
12%
Hemophagocytic Lymphohistiocytosis Syndrome
62%
Hemophagocytic Syndrome
100%
Lymphocytotoxicity
12%
Lymphoproliferative Disease
12%
Newborn Screening
12%
Patient with Genetic Disorder
12%
Ruxolitinib
12%
Salvage Therapy
12%
Stem Cell Therapy
87%
Thymocyte Antibody
12%
Pharmacology, Toxicology and Pharmaceutical Science
Albinism
12%
Alemtuzumab
12%
Emapalumab
12%
Etoposide
100%
Genetic Disorder
12%
Hemophagocytic Syndrome
100%
Lymphocytotoxicity
12%
Lymphoproliferative Disease
12%
Ruxolitinib
12%
Syndrome
12%
Thymocyte Antibody
12%
Immunology and Microbiology
Alemtuzumab
14%
Anti-Thymocyte Globulin
14%
Conditioning
14%
Emapalumab
14%
Hemophagocytic Lymphohistiocytosis
100%
Lymphocytotoxicity
14%
Newborn Screening
14%
Stem Cell Transplantation
100%